Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2004

View Archived Issues

Artekin may contribute to control of multidrug-resistant malaria

Enrollment complete in phase IV Visicol constipation study

Preclinical evidence for the antiviral efficacy of interferon alpha in SARS

Duloxetine improves voiding and quality of life of women with stress urinary incontinence

Clinical development of CAB-175 discontinued

Genzyme to acquire Ilex Oncology

Reorganization of indiplon agreements

Active Biotech discontinues discovery projects, focuses on development

Biovail acquires rights to novel formulations of eprosartan and carvedilol

Reolysin program update

Integrin alphavbeta3 antagonist and bone resorption inhibitor characterized for further development

Randomization completed in candesartan diabetic retinopathy program

Pharmacological characterization of novel DPP IV inhibitor K-579

Successful completion of first phase I trial for nebulized rAAT

Identification of neural stem cells in adult human brain

Improved response found in vitiligo patches with tacrolimus and excimer laser

Four related series of LDL receptor upregulators presented by GSK

New antibacterial oxazolidinones presented by Orchid researchers

Novel HDAC inhibitors prepared and tested by 4SC and G2M scientists

New glucosylceramide synthase inhibitors identified at Oxford Glycosciences

Aventis claims the preparation and use of novel cysteine protease inhibitors

New xanthine oxidase inhibitors for inflammation, reperfusion disorders and gout

Uriach presents immunomodulators and proapoptotic agents in a recent patent

Two novel series of glycogenphosphorylase a inhibitors under study at Aventis

Sinus and Allergy Health Partnership guidelines recommend Omnicef

Kirin announces phase I clinical trial of KRN-125 and other recent developments

Preclinical data supports use of INGN-241 regimens for lung, breast cancer

Satraplatin shows in vitro efficacy in tumor cells resistant to Taxotere and Taxol

Advanced Viral Research reports in vitro biologic effects of AVR-118

Approvable letter for Estorra

Zadaxin shows efficacy in preclinical invasive aspergillosis study

Investigation of Viagra for FSAD to close

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...